The Boehringer Ingelheim logo is shown at the BIO International Convention 2026, a meeting of pharmaceutical and biotechnology leaders in San Diego, California, U.S. June 23, 2026. REUTERS/Mike Blake

Owkin signs AI drug discovery deal with Boehringer for cancer, immunology

02 Sep 2026, 12:03 · CNA · Join

Read a summary of this article on FAST.
Get bite-sized news via a new
cards interface. Give it a try.
Click here to return to FAST Tap here to return to FAST
FAST

Sept 2 : AI company Owkin said on Wednesday it has signed a licensing deal with Germany's Boehringer Ingelheim, giving the drugmaker access to its AI research platform and patient data to speed up discovery of drugs for cancer and immunity-related diseases.

The deal adds Boehringer to a growing list of drugmakers using Owkin's AI technology, "K Pro". AstraZeneca licensed it in May, while Sanofi expanded its partnership with a five-year agreement in June.

Here are some more details:

• The deal builds on the companies' pilot project in 2025, in which Owkin used its patient tumor samples and related biological datasets to help Boehringer prioritize potential drug targets, the AI company's CEO, Thomas Clozel, told Reuters.

CNA Games

Guess Word
Crack the word, one row at a time

Buzzword
Create words using the given letters

Mini Sudoku
Tiny puzzle, mighty brain teaser

Mini Crossword
Small grid, big challenge

Word Search
Spot as many words as you can
Show More
Show Less

• Under the new pact, Owkin will license multimodal oncology data to Boehringer and will generate new data in immunology.

• Owkin licenses, sources and generates patient data in collaboration with its global patient data network.

• The companies did not disclose the financial terms of the agreement.

Newsletter